Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC

Conditions

• Stage III Non-small-Cell Lung Cancer

Interventions

• DRUG: Recombinant human endostatin
• DRUG: Etoposide (50mg/m2) IV (in the vein) on day 1 to day 5 of a 28-day cycle for 2 cycles
• DRUG: cisplatinum (50mg/m2) IV (in the vein) on day 1 and day 8 of a 28-day cycle for 2 cycles
• OTHER: laboratory biomarker analysis
• OTHER: CT perfusion imaging

Sponsor

Zhejiang Cancer Hospital

Collaborators

• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]